Dr. Philip Mease is a frequent author of many clinical guidelines recommended by the American College of Rheumatology. He is also a leading expert in psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA), ranked the most published worldwide in PsA and 12th in AxSpA over the past decade by Expertscape. He is the Director of Rheumatology Research at Providence/Swedish Health and a Clinical Professor at the University of Washington in Seattle. Dr. Mease holds degrees from Stanford University and completed his residency and fellowship at UW.

His research spans PsA, spondyloarthritis, rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, and fibromyalgia, focusing on disease mechanisms and emerging therapies. He authored over 660 journal articles and is known for his influential 2000 Lancet paper on anti-TNF therapy in PsA.

Dr. Mease has received numerous accolades, including lifetime achievement awards from the National Psoriasis Foundation and the Arthritis Foundation, and he is a Master of the American College of Rheumatology. He is active in various professional organizations, including GRAPPA, ASAS, and OMERACT, and serves in advisory roles for the FDA and ICHOM. His ongoing research includes overseeing registries and collaborating on AI studies in autoimmune diseases.